Delivery Order SPE2DB22D1103-SPE2DB25FTPK8
- Not listed
- The Defense Logistics Agency awarded a $11,097.32 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for Trelegy Ellipta 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 23, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,352.03 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This competitively awarded, firm fixed-price delivery order was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. The contract carries no set-aside designation, indicating that AmerisourceBergen competed openly against other qualified vendors. The pharmaceutical product will...
- The Defense Logistics Agency awarded a $36,573.09 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count) on November 10, 2025, with completion targeted for November 12, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $16,076.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $40,498.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract, which carries no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $50,306.61 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This non-competitive delivery order, which is scheduled for completion by August 29, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $11,207.26 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on October 31, 2025, with a completion date of November 3, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $11,102.78 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with an ultimate completion date of September 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $11.8K to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This firm fixed-price delivery order, which is scheduled for completion by October 30, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, and the...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTPK8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,554.00 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). Issued on June 9, 2025, with an ultimate completion date of June 10, 2025, this firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen regularly fulfills pharmaceutical procurement for military and veteran healthcare systems through the DLA Medical Supply Chain. Trelegy Ellipta is a combination respiratory medication used for managing chronic obstructive pulmonary disease, reflecting the company's role in supplying specialty medications and therapeutics to support Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 6/9/25 |